Knowledge base

1,824 claims across 19 domains

Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.

All 1,824 ai alignment 395 health 320 internet finance 306 space development 227 entertainment 169 grand strategy 141 collective intelligence 52 mechanisms 34 teleological economics 30 living agents 30 cultural dynamics 29 critical systems 24 energy 23 teleohumanity 18 living capital 10 robotics 5 manufacturing 5 unknown 3 technology 3

320 health claims

OpenEvidence became the fastest adopted clinical technology in history reaching 40 percent of US physicians daily within two years

OpenEvidence is the breakout story in clinical AI. Developed by Harvard and MIT researchers, it operates across 10,000+ hospitals, handles 8.5 million clinical consultations per month, and was the first AI to score 100% on the USMLE. Strategic content partnerships with NEJM and JAMA ground its respo

four competing payer provider models are converging toward value based care with vertical integration dominant today but aligned partnership potentially more durable

The competitive landscape for value-based care is consolidating around four structural models:

gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment

As of early 2026, 46 cell and gene therapies have FDA approval, with prices concentrated in the $2-4M range: Casgevy ($2.2M for sickle cell), Lyfgenia ($3.1M), Zolgensma ($2.1M for SMA), Hemgenix ($3.5M for hemophilia B). These are all ex vivo therapies -- harvest cells, edit them, reinfuse -- requi

GLP 1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035

The GLP-1 receptor agonist market reached $63-70 billion in 2025, with Eli Lilly's Mounjaro/Zepbound generating over $36 billion and Novo Nordisk's semaglutide products contributing another $48.9 billion. The market is projected to reach $250-315 billion by 2035 at 12.8-17.5% CAGR.

personalized mRNA cancer vaccines show sustained 49 percent reduction in melanoma recurrence after five years representing a genuinely novel therapeutic paradigm

The Moderna/Merck partnership on intismeran (mRNA-4157/V940) represents the most advanced non-COVID mRNA therapeutic and a genuinely novel approach to cancer treatment. The vaccine is manufactured individually for each patient: tumor DNA is sequenced, up to 34 neoantigens are selected, and personali

the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline

The fundamental tension in healthcare economics: medicine can now cure diseases that were previously only manageable, but the cures are expensive and the newly treatable population is enormous. The transition period through ~2035 sees rising costs as new therapies launch at premium prices and reach

prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without the pricing power that justifies it for near zero marginal cost software

The prescription digital therapeutics (PDT) model attempted to replicate pharmaceutical business logic -- FDA clearance followed by insurance reimbursement -- without pharmaceutical economics. All three flagship companies collapsed:

AI diagnostic triage achieves 97 percent sensitivity across 14 conditions making AI first screening viable for all imaging and pathology

The FDA has authorized 1,356 AI-enabled medical devices as of December 2025, up 8.5% from the prior report. Radiology dominates: 1,039 devices (77% of all authorizations), growing from 6 clearances in 2015 to 221 in 2023. In January 2026, Aidoc received clearance for healthcare's first comprehensive

social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem

In May 2023, US Surgeon General Vivek Murthy released the landmark advisory "Our Epidemic of Loneliness and Isolation," establishing loneliness as a public health crisis. The data: loneliness carries mortality risk equivalent to smoking 15 cigarettes per day, social isolation among older adults acco

Oura controls 80 percent of the smart ring market with patent defended form factor while a demographic pivot from fitness enthusiasts to wellness focused women drives 250 percent sales growth

Oura has achieved a rare combination in consumer hardware: dominant market share (80% of smart rings), accelerating revenue ($147M → $225M → $500M from 2022 to 2024), and a defensible form factor protected by patent litigation. The October 2025 $900M raise at $11B valuation (led by NEA, General Cata

continuous health monitoring is converging on a multi layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware

The attractor state for health monitoring is not a single device but a multi-layer sensor architecture. Layer 1 is ambient always-on sensing -- smart rings or earbuds for continuous HR, HRV, SpO2, and temperature (the ring form factor wins for optical sensing due to high finger perfusion). Layer 2 i

the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification

The FDA's January 2026 guidance update established a critical distinction: non-invasive wearables estimating health metrics can claim general wellness status if they avoid disease/diagnostic/clinical management claims. A fitness tracker can detect "patterns and events that warrant a closer look" --

medicare advantage spending gap grew 47x while enrollment doubled indicating scale worsens overpayment problem

The federal spending gap between Medicare Advantage and fee-for-service Medicare grew from $18 billion in 2015 to $84 billion in 2025 — a 4.7x increase. During the same period, MA enrollment roughly doubled from ~16 million to 34 million beneficiaries. This means the overpayment problem is getting w

medicare advantage crossed majority enrollment in 2023 marking structural transformation from supplement to dominant program

Medicare Advantage enrollment crossed the 50% threshold in 2023 (30.8M enrollees, 51% penetration) and reached 54% by 2025 (34.1M enrollees). This represents a structural inflection point where managed care became the default Medicare experience rather than an alternative. The trajectory is accelera

chronic condition special needs plans grew 71 percent in one year indicating explosive demand for disease management infrastructure

C-SNPs (Chronic Condition Special Needs Plans) grew 71% from 2024 to 2025, reaching 1.2 million enrollees and representing 16% of all Special Needs Plan enrollment. This is the fastest-growing segment of Medicare Advantage and signals a structural shift toward managed care models specifically design

medicare advantage market is an oligopoly with unitedhealthgroup and humana controlling 46 percent despite nominal plan choice

The Medicare Advantage market exhibits classic oligopoly structure: UnitedHealthGroup (9.9M enrollees, 29%) and Humana (5.7M enrollees, 17%) together control 46% of all MA enrollment. This concentration exists despite beneficiaries having an average of 9 plan options, with 36% of beneficiaries havin

gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks

Healthcare systems that require primary care referrals for specialty access (gatekeeping) face a fundamental tradeoff: they improve primary care coordination and reduce inappropriate specialty utilization, but they concentrate demand at referral choke points that become capacity bottlenecks under re

nhs demonstrates universal coverage without adequate funding produces excellent primary care but catastrophic specialty access

The NHS provides the clearest evidence that universal coverage alone does not guarantee good health outcomes across all dimensions of care. Despite ranking **3rd overall** in the Commonwealth Fund's Mirror Mirror 2024 international comparison, the NHS simultaneously exhibits the worst specialty acce

acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef

The American College of Cardiology's first major statement on anti-obesity medications in heart failure explicitly states that 'insufficient evidence exists to confidently conclude that semaglutide and tirzepatide reduce HF events in individuals with HFpEF and obesity' despite acknowledging improvem

healthexperimental

the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already served rather than expanding access

The US behavioral health market was valued at $89-95 billion in 2024, projected to reach $165 billion by 2034. But the supply side cannot keep pace. SAMHSA projects a shortage of approximately 250,510 professionals across nine critical mental health occupations, with demand for behavioral health pra